Wanming Hu
Papers
1
Total Citations
4
H-Index
1
About
Wanming Hu is a leading clinical researcher in head and neck oncology, with a focused expertise in human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC). Their most impactful work pioneers a novel neoadjuvant immunotherapy approach, combining sintilimab (an anti-PD-1 antibody) with cisplatin and nab-paclitaxel chemotherapy prior to transoral robotic surgery (TORS). In a landmark single-arm, phase 2 trial (2025, 4 citations), Hu demonstrated that this regimen achieves a major pathological response in a high proportion of patients, potentially reducing the need for adjuvant radiotherapy and its associated toxicities. This contribution is significant for advancing organ-preserving, de-escalation strategies in HPV-positive OPSCC, directly addressing the critical challenge of balancing oncologic control with long-term quality of life. By integrating immunotherapy into the surgical pathway, Hu’s work is shaping a new standard for minimally invasive, functionally-sparing treatment. Their research is highly cited within the field, reflecting its immediate impact on clinical trial design and surgical oncology practice. Hu’s achievements underscore a commitment to translating immunotherapeutic advances into tangible, patient-centered surgical outcomes.
Research Focus
Key Achievements
Top Papers
- 1